Risk-based prostate cancer screening.

scientific article

Risk-based prostate cancer screening. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EURURO.2011.11.029
P932PMC publication ID4716732
P698PubMed publication ID22134009

P50authorMonique J. RoobolQ73993906
Andrew VickersQ20055453
Fritz H. SchröderQ24517867
P2093author name stringGerald L Andriole
Xiaoye Zhu
Peter C Albertsen
P2860cites workComparison of Prostate Specific Antigen Velocity in Screened Versus Referred Patients With Prostate CancerQ59563480
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohortQ62778214
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate CancerQ63965934
Diabetes and prostate cancer risk in the REDUCE trialQ63966154
Does PSA velocity predict prostate cancer in pre-screened populations?Q63966358
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate diseaseQ67897074
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostateQ69003522
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancerQ71667362
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocityQ71688012
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?Q74591846
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastasesQ77386806
Role of family history and ethnicity on the mode and age of prostate cancer presentationQ77707681
Prostate-specific antigen velocity and prostate cancer gleason grade and stageQ79852066
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factorsQ80388277
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsyQ82228594
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC RotterdamQ83444588
Screening: should more biopsies be taken in larger prostates?Q83900988
Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancerQ85111035
Head-to-head comparison of two online nomograms for prostate biopsy outcome predictionQ85114789
Global cancer statisticsQ22241238
Cancer statistics, 2010Q27860525
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)Q28254022
American Cancer Society guideline for the early detection of prostate cancer: update 2010Q28274848
Screening and prostate-cancer mortality in a randomized European studyQ29617485
The new human tissue kallikrein gene family: structure, function, and association to disease.Q30328102
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL ConsortiumQ30491647
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, SwedenQ31161981
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyQ33320071
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic reviewQ33338725
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancerQ33833602
Mortality results from the Göteborg randomised population-based prostate-cancer screening trialQ33873969
DD3: a new prostate-specific gene, highly overexpressed in prostate cancerQ33884277
The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy seriesQ33896042
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replicationQ33897630
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohortQ33937634
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic testQ34126444
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Q34130128
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.Q34291551
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomyQ34332665
Human prostate cancer risk factorsQ34360616
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsQ34425649
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).Q34555011
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screeningQ34561148
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerQ34577447
Decision curve analysis: a novel method for evaluating prediction modelsQ34581068
NCCN clinical practice guidelines in oncology: prostate cancer early detectionQ34616553
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionQ34677200
Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening TrialQ34679266
Impact of Comorbidity on Survival Among Men With Localized Prostate CancerQ34879348
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?Q35118406
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen RangeQ35119292
A systematic review and meta-analysis of familial prostate cancer riskQ35142714
Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysisQ35563089
Populations at high risk for prostate cancerQ35609524
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level aloneQ35924515
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based studyQ35945224
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Q36142693
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening studyQ36509148
The impact of obesity on prostate cancerQ36834176
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curabilityQ37104344
Risk of developing prostate cancer in the future: overview of prognostic biomarkers.Q37449789
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerQ37457676
A framework for the identification of men at increased risk for prostate cancer.Q37598425
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactQ37632049
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised diseaseQ37807744
Contemporary role of prostate cancer gene 3 in the management of prostate cancerQ37837431
Tumour markers in prostate cancer III: biomarkers in urine.Q37878473
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.Q38434213
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening studyQ38447309
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysisQ38466779
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancerQ39370687
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greaterQ39535872
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).Q39676593
Cancer of the prostate: epidemiology and aetiologyQ39684035
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerQ39722492
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.Q39743716
Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialQ39752227
APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancerQ39752513
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationQ39778617
Assessing individual risk for prostate cancerQ39809092
Characteristics of prostate cancer detected by digital rectal examination onlyQ39827114
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsyQ39852032
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.Q39899527
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionQ39904254
Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohortQ39939334
Prediction of prostate cancer in unscreened men: external validation of a risk calculatorQ39963193
The Prostate Cancer Risk Calculator From the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in Contemporary Referral PatientsQ39963357
Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsyQ39972993
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical settingQ39978620
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.Q39984016
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculatorsQ40008682
Defining increased future risk for prostate cancer: evidence from a population based screening cohort.Q40027426
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of AgingQ40687312
Variation in KLK genes, prostate-specific antigen and risk of prostate cancerQ42725643
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.Q43166284
Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family membersQ43726748
Balancing the harms and benefits of early detection of prostate cancer.Q43926844
Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, NorwayQ44259125
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trialQ45062085
Comorbidity and competing risks for mortality in men with prostate cancer.Q45064053
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.Q45216796
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressivenessQ45348221
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 casesQ46182115
High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates.Q46661260
Prostate volume and adverse prostate cancer features: fact not artifactQ46904796
Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and raceQ46972571
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database studyQ47364687
A graphical device to represent the outcomes of a logistic regression analysis.Q47392558
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate CancerQ50717991
Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).Q51584281
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.Q51780643
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease1Q56637802
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened PQ57239006
Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk CalculatorsQ57941019
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
P304page(s)652-661
P577publication date2011-11-24
P1433published inEuropean UrologyQ15763991
P1476titleRisk-based prostate cancer screening
P478volume61

Reverse relations

cites work (P2860)
Q90062138A Novel Tanshinone Analog Exerts Anti-Cancer Effects in Prostate Cancer by Inducing Cell Apoptosis, Arresting Cell Cycle at G2 Phase and Blocking Metastatic Ability
Q36730143A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice--the ProCaRis study: study protocol
Q38957244A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy
Q36765312A personalized automated messaging system to improve adherence to prostate cancer screening: research protocol
Q35809905Association between tumor-associated macrophages and microvessel density on prostate cancer progression.
Q46918731Association of healthcare barriers with prostate-specific antigen screening among African-American and Afro-Caribbean men.
Q38965360Clarifying the PSA grey zone: The management of patients with a borderline PSA.
Q36627182Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma
Q33581483Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.
Q35569530Coupling of prostate and thyroid cancer diagnoses in the United States
Q40417671Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel
Q53110750Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style
Q35736485Ethnicity and prostate cancer: the way to solve the screening problem?
Q40284624Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
Q35993964How should prostate specific antigen be interpreted?
Q97543913Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients' survival and responses to androgen deprivation therapies in Indonesian patients cohort
Q37671113Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Q57068289Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression
Q38203983International perspectives on screening.
Q45373509Loss of Sun2 promotes the progression of prostate cancer by regulating fatty acid oxidation
Q58794466Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer
Q36520508Overdiagnosis of Prostate Cancer
Q45864090Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Q51312747Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Q57176659Predictors of participation in risk-based prostate cancer screening
Q35732225Prognostic significance of multiple kallikreins in high-grade astrocytoma
Q40327112Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer
Q45841914Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends
Q37609671Prostate cancer screening and the management of clinically localized disease
Q51771288Prostate cancer screening in Europe and Asia.
Q37155070Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
Q34354430Prostate-specific antigen screening in prostate cancer: perspectives on the evidence
Q38408501Prostate-specific antigen-based prostate cancer screening: Past and future
Q37706084Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.
Q38068114Risk stratification in prostate cancer screening.
Q42391610The benefits of risk assessment tools for prostate cancer
Q89594348The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial
Q59563272Update of randomized trials for prostate cancer screening
Q40281409Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Q44417584[-2]proPSA is an early marker for prostate cancer aggressiveness

Search more.